FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

header-info

The U.S. Food and Drug Administration (FDA) is warning that results from the phase III DUO clinical trial show a possible increased risk of death with duvelisib compared to ofatumumab among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).